{"entity":{"id":"eurofarma","kind":"company","name":"Eurofarma","aka":["Eurofarma Laboratorios S.A.","Eurofarma Laboratórios"],"tldr":"Eurofarma is a São Paulo pharmaceutical group founded in 1972, one of the largest Brazilian-owned drug makers, with an oncology portfolio and phase 3 trials it leads in Latin America.","summary":"Eurofarma Laboratórios, headquartered in São Paulo and founded in 1972, is a privately held Brazilian pharmaceutical group operating across Latin America with prescription, generic and hospital medicines, including an oncology line. It is lead sponsor of phase 3 cancer trials registered on ClinicalTrials.gov. Its registered cancer trials compare its own goserelin, filgrastim and pegfilgrastim with the originator products in prostate and breast cancer, and test nimotuzumab with chemoradiotherapy in head and neck, oesophageal and cervical cancer (ClinicalTrials.gov NCT03936218, NCT03936933, NCT01079676, NCT02768714, NCT01345084, NCT01249352, NCT01301612).","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Eurofarma","links":[{"label":"Official website","url":"https://www.eurofarma.com.br"},{"label":"ClinicalTrials.gov: trials led by Eurofarma","url":"https://clinicaltrials.gov/search?lead=Eurofarma"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q23777937"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","breast-hr-positive","head-and-neck","esophageal","cervical"],"sections":[],"technologies":["g-csf-growth-factors","biosimilar-manufacturing"],"targets":[],"drugs":["goserelin","filgrastim","pegfilgrastim","nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"São Paulo","country":"BR","companyType":"pharma","website":"https://www.eurofarma.com.br","founded":1972,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/eurofarma/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/"},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/"}],"drug":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"},{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}